Abrocitinib Therapeutic Cheat Sheet
Abrocitinib is an oral, once-daily selective Janus kinase 1 (JAK1) inhibitor approved for moderate-to-severe atopic dermatitis. It can provide rapid improvement in pruritus and skin disease and is a useful treatment option for many patients. As an oral medication, it may also be preferred by patients who want to avoid injections. When prescribing abrocitinib, it is important to discuss laboratory …
Abrocitinib is an oral, once-daily selective Janus kinase 1 (JAK1) inhibitor approved for moderate-to-severe atopic dermatitis. It can provide rapid improvement in pruritus and skin disease and is a useful treatment option for many patients. As an oral medication, it may also be preferred by patients who want to avoid injections. When prescribing abrocitinib, it is important to discuss laboratory … 
Scarring alopecias in skin of color are increasingly recognized and remain a major cause of irreversible hair loss. During the 2025 Skin of Color Update in New York City, Susan C. Taylor, MD, presented an updated clinical approach to identifying and managing lichen planopilaris (LPP), frontal fibrosing alopecia (FFA), and central centrifugal cicatricial alopecia (CCCA) with a focus on early detect … 
Diagnosing systemic disease requires connecting the dots from the microscope to the bedside, according to Mayo Clinic dermatologist and dermatopathologist Olayemi Sokumbi, MD, FAAD.
In this Next Steps in Derm interview, in partnership with the ODAC Dermatology Conference, Dr. Sokumbi outlines how she makes diagnostic decisions, including thinking beyond the skin. As a dermatologic detective of … 
Lebrikizumab is a humanized immunoglobulin G4 (IgG4) monoclonal antibody that selectively targets IL-13, a key cytokine implicated in the pathogenesis of type 2 inflammatory diseases.1 Lebrikizumab binds IL-13 with high affinity and a slow dissociation rate, which prevents heterodimerization of the IL-13 receptor alpha-1 subunit (IL-13Rα1) with the IL-4 receptor alpha (IL-4Rα) signaling complex. … 
Pigmentary change often drives patients to seek dermatologic care, yet sometimes the cause is more than skin deep. Next Steps in Derm, in partnership with Skin of Color Update, interviewed conference co-chair Dr. Andrew F. Alexis about the skin signs of systemic disease in patients with darker skin tones. Watch as Dr. Alexis shares stories of the diseases he’s diagnosed in clinical practice. Le …